The Phase 3 results in China are encouraging for Kailera Therapeutics, which holds rights to the molecule in the rest of the world. The startup is preparing a global clinical development program for this drug, a once-weekly injectable GLP-1 and GIP receptor agonist.
The post Hengrui Pharma’s Potential Rival to El Lilly’s Zepbound Leads to 18% Weight Loss in Key Study appeared first on MedCity News.
